By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

DelMar Pharmaceuticals 

999 West Broadway
Suite 720
  British Columbia  V5Z 1K5  Canada
Phone: 1-604-629-5989 Fax:


SEARCH JOBS


Industry
Pharmaceutical






Company News
DelMar Pharma Announces Second Quarter Fiscal Year 2017 Financial Results 2/13/2017 8:30:53 AM
DelMar Pharma Announces Dosing Of The First Patient In Phase Two Clinical Trial Of VAL-083 For MGMT-Unmethylated Recurrent Glioblastoma Multiforme (GBM) 2/13/2017 7:01:45 AM
DelMar Pharma Release: Company And MD Anderson Cancer Center Initiate New Phase Two Clinical Trial Of VAL-083 For MGMT-Unmethylated Recurrent Glioblastoma Multiforme (GBM) 1/25/2017 9:52:26 AM
DelMar Pharma Receives Additional Non-Dilutive Funding From The Government Of Canada To Support Expanded Research With Lead Product Candidate VAL-083 1/9/2017 9:30:51 AM
DelMar Pharma Receives Notice Of Allowance From The US Patent And Trademark Office For Key Patent For VAL-083 12/14/2016 6:52:06 AM
DelMar Pharma Delivers An Address And Presents An Overview Of Upcoming GBM Trials With VAL-083 At The CNS Anticancer Drug Discovery Development Conference And Society For NeuroOncology Annual Meeting 11/21/2016 9:09:29 AM
DelMar Pharma Announces First Quarter Fiscal Year 2017 Financial Results and Corporate Update 11/14/2016 11:32:39 AM
DelMar Pharma Announces Upcoming Scientific Conference Presentations 10/13/2016 9:33:49 AM
DelMar Pharma Presents Data Supporting The Potential Of VAL-083 As A New Treatment For Ovarian Cancer At The 11th Biennial Ovarian Cancer Research Symposium 9/13/2016 8:54:49 AM
DelMar Pharma And Accurexa To Collaborate In The Development Of A Novel Combination Chemotherapy For The Local Treatment Of Brain Cancer 9/7/2016 9:02:25 AM
12345678910...
//-->